Notably, a clinical trial in NSCLC patients examining the combination of entinostat with the EGFR inhibitor erlotinib in comparison to erlotinib alone found a small increase in progression-free survival (PFS) [94]. Here, EGFR is linked to non-small cell lung carcinoma.